CEL-SCI Corporation: Investors' Caution Warranted [Seeking Alpha]
Cel-Sci Corporation (CVM)
NASDAQ:AMEX Investor Relations:
cel-sci.com/investor_relations.html
Company Research
Source: Seeking Alpha
CEL-SCI Corporation: Investors' Caution Warranted Feb. 28, 2020 8:32 AM ET | About: CEL-SCI Corporation (CVM) by: C. C. Abbott Biotech, long-term horizon, small-cap, micro-cap Summary On Feb 26, 2020, the CEO of CEL-SCI Corporation issued a letter to its shareholders concerning their global pivotal phase-3 trial. The trial, which the company started 9 years ago, investigates CEL-SCI's Multikine immuherapy as a neoadjuvant treatment in advanced primary squamous cell carcinoma of the head and neck. The letter explains what the company thinks about the trial delay and it ends with an optimistic exclamation. ("We thank you for your support. We believe!"). I take a close look at the letter, the company's current presentation to the investors, and their 2019 annual report. In my opinion, a negative outcome (trial failure) is more likely, contrary to the company's estimation. Thus investors should exercise caution in their consideration. My rating for CVM is Sell. Introduction For any rea
Show less
Read more
Impact Snapshot
Event Time:
CVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVM alerts
High impacting Cel-Sci Corporation news events
Weekly update
A roundup of the hottest topics
CVM
News
- CEL-SCI Co. (NYSE: CVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025Business Wire
- CEL-SCI files to sell 1M shares of common stock for holders [Seeking Alpha]Seeking Alpha
- FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsBusiness Wire
- CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerBusiness Wire
CVM
Earnings
- 8/14/24 - Miss
CVM
Sec Filings
- 11/15/24 - Form 8-K
- 11/13/24 - Form 8-K
- 11/8/24 - Form EFFECT
- CVM's page on the SEC website